BioXcel Therapeutics, Inc. Common Stock (BTAI) - Nasdaq

BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

CouponFollow Extension

$127
OFF

BTAI Stock Price | BioXcel Therapeutics Inc. Stock Quote (U.S.: …

6 days from now

4 days ago · BioXcel Therapeutics price target cut to $127 from $150 at Truist Securities, stock rated buy. Apr. 1, 2021 at 6:59 a.m. ET by Tonya Garcia.

marketwatch.com

$60
OFF

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

6 days from now

1 day ago · BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 …

marketbeat.com

$25
OFF

BioXcel Therapeutics, Inc. (BTAI) - Stock Analysis

6 days from now

BioXcel Therapeutics Announces $25 Million Registered Direct Offering. NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) …

stockanalysis.com

$7
OFF

BioXcel Therapeutics, Inc. Stock (BTAI) - Quote Nasdaq

6 days from now

Nov 11, 2024 · Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating. Mar. 14. MT. UBS Adjusts BioXcel Therapeutics Price Target to $3.50 …

marketscreener.com

89%
OFF

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights ...

6 days from now

Nov 15, 2024 · BioXcel Therapeutics Inc (NASDAQ:BTAI) reported an 89% increase in net revenue for the nine months ended September 30, 2024, compared to the same period in …

yahoo.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 ... - Markets Insider

6 days from now

1 day ago · Nov. 22, 2024, 08:16 AM. NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company …

businessinsider.com

$0.58
OFF

BioXcel Therapeutics Stock Price | BTAI Stock Quote, News, And …

6 days from now

Discover the best brokers for stock trading and ordering other assets! On Wednesday 11/20/2024 the closing price of the BioXcel Therapeutics Inc Registered Shs share was $0.58 on BTT. …

businessinsider.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million

6 days from now

1 day ago · NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …

globenewswire.com

$40
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · Cash and cash equivalents totaled $40.4 million as of September 30, 2024. ConferenceCall and Webcast. BioXcel Therapeutics will host a conference call and webcast …

businessinsider.com

$0.57
OFF

Bioxcel Therapeutics Stock Price Today (NASDAQ: BTAI) Quote, …

6 days from now

Nov 15, 2024 · With Bioxcel Therapeutics stock trading at $0.57 per share, the total value of Bioxcel Therapeutics stock (market capitalization) is $23.14M. Bioxcel Therapeutics stock was …

wallstreetzen.com

$3449
OFF

BioXcel Therapeutics Inc (BTAI) - Investing.com Canada

6 days from now

Oct. 21, 2024. BioXcel Therapeutics executive sells shares worth $3,449. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has reported a recent sale of common stock by one of its top executives. …

investing.com

$40
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · Cash and cash equivalentstotaled $40.4 million as of September 30, 2024. ConferenceCall and Webcast. BioXcel Therapeutics will host a conference call and webcast …

yahoo.com

$3449
OFF

BioXcel Therapeutics Share Price Today | NASDAQ: BTAI Stock

6 days from now

04 Oct 2024. BioXcel Therapeutics executive sells shares worth $3,449. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has reported a recent sale of common stock by one of its top executives. …

investing.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million Public …

6 days from now

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence …

bioxceltherapeutics.com

FAQs about BioXcel Therapeutics, Inc. Common Stock (BTAI) - Nasdaq Coupon?

Who owns bioxcel Therapeutics (btai)?

It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View BioXcel Therapeutics, Inc. BTAI stock quote prices, financial information, real-time forecasts, and company news from CNN. ...

Who owns bioxcel Therapeutics Inc?

It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. BTAI | Complete BioXcel Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Does bioxcel Therapeutics (btai) have earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) reported earnings on Thursday, May, 9th. The company reported ($0.87) EPS, missing analysts' consensus estimates of ($0.68) by $0.19. The business earned $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. ...

What is the price target for bioxcel Therapeutics Inc registered SHS (BTT)?

Compared to the opening price on Thursday 08/22/2024 on BTT of $0.67, this is a drop of 2.47%. BioXcel Therapeutics Inc Registered Shs's market capitalization is $27.14 M by 40.74 M shares outstanding. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Selling, General & Admin. Exp. ...

How much did bioxcel Therapeutics raise in an IPO?

BioXcel Therapeutics (BTAI) raised $60 million in their IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. $60 million was raised in the IPO. ...

Is bioxcel Therapeutics a good stock to buy?

According to analysts, BioXcel Therapeutics has a consensus rating of Hold. The company's average rating score is 2.43, based on 3 buy ratings, 4 hold ratings, and no sell ratings. BioXcel Therapeutics has only been the subject of 3 research reports in the past 90 days. ...